Literature DB >> 32954444

Long-term glucose variability and risk of nephropathy complication in UKPDS, ACCORD and VADT trials.

Jin J Zhou1,2, Ruth Coleman3, Rury R Holman3, Peter Reaven4.   

Abstract

Entities:  

Keywords:  Intensive glycaemic control; Long-term glycaemic variability; Microvascular complications; Nephropathy; Type 2 Diabetes

Year:  2020        PMID： 32954444      PMCID： PMC7573923          DOI： 10.1007/s00125-020-05273-7

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  8 in total

Review 1.  Visit-to-visit variability of blood pressure and cardiovascular disease and all-cause mortality: a systematic review and meta-analysis.

Authors:  Keith M Diaz; Rikki M Tanner; Louise Falzon; Emily B Levitan; Kristi Reynolds; Daichi Shimbo; Paul Muntner
Journal:  Hypertension       Date:  2014-07-28       Impact factor: 10.190

2.  Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.

Authors:  Faramarz Ismail-Beigi; Timothy Craven; Mary Ann Banerji; Jan Basile; Jorge Calles; Robert M Cohen; Robert Cuddihy; William C Cushman; Saul Genuth; Richard H Grimm; Bruce P Hamilton; Byron Hoogwerf; Diane Karl; Lois Katz; Armand Krikorian; Patrick O'Connor; Rodica Pop-Busui; Ulrich Schubart; Debra Simmons; Harris Taylor; Abraham Thomas; Daniel Weiss; Irene Hramiak
Journal:  Lancet       Date:  2010-06-30       Impact factor: 79.321

3.  Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.

Authors:  Sophia Zoungas; Hisatomi Arima; Hertzel C Gerstein; Rury R Holman; Mark Woodward; Peter Reaven; Rodney A Hayward; Timothy Craven; Ruth L Coleman; John Chalmers
Journal:  Lancet Diabetes Endocrinol       Date:  2017-03-30       Impact factor: 32.069

4.  Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.

Authors:  Yoichiro Hirakawa; Hisatomi Arima; Sophia Zoungas; Toshiharu Ninomiya; Mark Cooper; Pavel Hamet; Giuseppe Mancia; Neil Poulter; Stephen Harrap; Mark Woodward; John Chalmers
Journal:  Diabetes Care       Date:  2014-05-08       Impact factor: 19.112

5.  Glucose control and vascular complications in veterans with type 2 diabetes.

Authors:  William Duckworth; Carlos Abraira; Thomas Moritz; Domenic Reda; Nicholas Emanuele; Peter D Reaven; Franklin J Zieve; Jennifer Marks; Stephen N Davis; Rodney Hayward; Stuart R Warren; Steven Goldman; Madeline McCarren; Mary Ellen Vitek; William G Henderson; Grant D Huang
Journal:  N Engl J Med       Date:  2008-12-17       Impact factor: 91.245

6.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

7.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

Review 8.  Long-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis.

Authors:  Catherine Gorst; Chun Shing Kwok; Saadia Aslam; Iain Buchan; Evangelos Kontopantelis; Phyo K Myint; Grant Heatlie; Yoon Loke; Martin K Rutter; Mamas A Mamas
Journal:  Diabetes Care       Date:  2015-12       Impact factor: 19.112
  8 in total
  5 in total

1.  GWAS of longitudinal trajectories at biobank scale.

Authors:  Seyoon Ko; Christopher A German; Aubrey Jensen; Judong Shen; Anran Wang; Devan V Mehrotra; Yan V Sun; Janet S Sinsheimer; Hua Zhou; Jin J Zhou
Journal:  Am J Hum Genet       Date:  2022-02-22       Impact factor: 11.043

Review 2.  Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications.

Authors:  Bao Sun; Zhiying Luo; Jiecan Zhou
Journal:  Cardiovasc Diabetol       Date:  2021-01-07       Impact factor: 9.951

3.  Heterogeneous treatment effects of intensive glycemic control on major adverse cardiovascular events in the ACCORD and VADT trials: a machine-learning analysis.

Authors:  Justin A Edward; Kevin Josey; Gideon Bahn; Liron Caplan; Jane E B Reusch; Peter Reaven; Debashis Ghosh; Sridharan Raghavan
Journal:  Cardiovasc Diabetol       Date:  2022-04-27       Impact factor: 8.949

4.  Refining determinants of associations of visit-to-visit blood pressure variability with cardiovascular risk: results from the Action to Control Cardiovascular Risk in Diabetes Trial.

Authors:  Daniel S Nuyujukian; Jin J Zhou; Juraj Koska; Peter D Reaven
Journal:  J Hypertens       Date:  2021-11-01       Impact factor: 4.844

5.  Fasting Glucose Variability as a Risk Indicator for End-Stage Kidney Disease in Patients with Diabetes: A Nationwide Population-Based Study.

Authors:  Da Young Lee; Jaeyoung Kim; Sanghyun Park; So Young Park; Ji Hee Yu; Ji A Seo; Nam Hoon Kim; Hye Jin Yoo; Sin Gon Kim; Kyung Mook Choi; Sei Hyun Baik; Kyungdo Han; Nan Hee Kim
Journal:  J Clin Med       Date:  2021-12-18       Impact factor: 4.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.